Merck KGaA (OTCMKTS:MKKGY – Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 46,022 shares, a decrease of 68.5% from the October 15th total of 146,247 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 104,760 shares, the days-to-cover ratio is currently 0.4 days.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on MKKGY shares. UBS Group cut Merck KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. Zacks Research raised Merck KGaA from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a Hold rating. According to MarketBeat, the stock currently has a consensus rating of “Hold”.
Get Our Latest Report on MKKGY
Merck KGaA Trading Up 1.5%
Shares of OTCMKTS MKKGY traded up $0.50 on Friday, reaching $33.12. 20,663 shares of the company traded hands, compared to its average volume of 94,101. The stock has a market capitalization of $21.40 billion, a PE ratio of 17.07, a P/E/G ratio of 2.93 and a beta of 0.92. Merck KGaA has a fifty-two week low of $23.73 and a fifty-two week high of $34.19. The company has a current ratio of 1.69, a quick ratio of 1.09 and a debt-to-equity ratio of 0.37. The company has a 50 day moving average of $31.72 and a 200 day moving average of $30.08.
About Merck KGaA
Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.
See Also
- Five stocks we like better than Merck KGaA
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
